Do Not Assume Symptoms Indicate Failure of Anti-Tumor Necrosis Factor Therapy in Crohn's Disease

Clinical Gastroenterology and Hepatology

Volumn 9, Issue 5, 2011, Pages 395-399

  Bruining, David H ^a   Sandborn, William J ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti TNF Therapy; Crohn's Disease; Treatment Failure

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CALGRANULIN; CERTOLIZUMAB PEGOL; INFLIXIMAB; LACTOFERRIN; MERCAPTOPURINE; MESALAZINE; NATALIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DEPRESSION; DIARRHEA; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; IRRITABLE COLON; PROPHYLAXIS; RECURRENT DISEASE; STEATORRHEA; TREATMENT FAILURE; ULCERATIVE COLITIS;

CROHN DISEASE; DRUG MONITORING; HUMANS; IMMUNOLOGIC FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79954997149     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.01.019     Document Type: Article

References (32)

1. Rutgeerts P., Feagan B.G., Lichtenstein G.R., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004, 126:402-413.
2. Rutgeerts P., Diamond R.H., Bala M., et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006, 63:433-442.
3. Hara A.K., Alam S., Heigh R.I., et al. Using CT enterography to monitor Crohn's disease activity: a preliminary study. AJR Am J Roentgenol 2008, 190:1512-1516.
4. Feagan B.G., Panaccione R., Sandborn W.J., et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008, 135:1493-1499.
5. Regueiro M., Schraut W., Baidoo L., et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009, 136:441-450.
6. Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
7. Toruner M., Loftus E.V., Harmsen W.S., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134:929-936.
8. Modigliani R., Mary J.Y., Simon J.F., et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease: evolution on prednisolone-Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990, 98:811-818.
9. Jones J., Loftus E.V., Panaccione R., et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008, 6:1218-1224.
10. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002, 359:1541-1549.
11. Hanauer S.B., Korelitz B.I., Rutgeerts P., et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004, 127:723-729.
12. Cheifetz A.S., Kornbluth A.A., Legnani P., et al. The risk of retention of the capsule endoscope in patients with known or suspected Crohn's disease. Am J Gastroenterol 2006, 101:2218-2222.
13. Signorelli C., Rondonotti E., Villa F., et al. Use of the Given Patency System for the screening of patients at high risk for capsule retention. Dig Liver Dis 2006, 38:326-330.
14. Bruining D.H., Siddiki H.A., Fletcher J.G., et al. Prevalence of penetrating disease and extraintestinal manifestations of Crohn's disease detected with CT enterography. Inflamm Bowel Dis 2008, 14:1701-1706.
15. Cosnes J., Cattan S., Blain A., et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002, 8:244-250.
16. Thia K., Sandborn W.J., Harmsen S.W., et al. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010, 139:1147-1155.
17. Cosnes J., de Parades V., Carbonnel F., et al. Classification of the sequelae of bowel resection for Crohn's disease. Br J Surg 1994, 81:1627-1631.
18. Castiglione F., Rispo A., Di Girolamo E., et al. Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease. Aliment Pharmacol Ther 2003, 18:1107-1112.
19. Issa M., Vijayapal A., Graham M.B., et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007, 5:345-351.
20. Kim J.J., Simpson N., Klipfel N., et al. Cytomegalovirus infection in patients with active inflammatory bowel disease. Dig Dis Sci 2010, 55:1059-1065.
21. Minderhoud I.M., Oldenburg B., Wismeijer J.A., et al. IBS-like symptoms in patients with inflammatory bowel disease in remission: relationships with quality of life and coping behavior. Dig Dis Sci 2004, 49:469-474.
22. Persoons P., Vermeire S., Demyttenaere K., et al. The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab. Aliment Pharmacol Ther 2005, 22:101-110.
23. Sandborn W.J., Abreu M., Geert D., et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 2010, 8:688-695.
24. Sandborn W.J., Rutgeerts P., Enns R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007, 146:829-838.
25. Allez M., Vermeire S., Mozziconacci N., et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 2010, 31:92-101.
26. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
27. Maser E.A., Villela R., Silverberg M.S., et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:1248-1254.
28. Afif W., Loftus E.V., Faubion W.A., et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010, 105:1133-1139.
29. Colombel J.-F., Sandborn W.J., Rutgeerts P., et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol 2009, 104:1170-1179.
30. Sandborn W.J., Colombel J.F., Schreiber S., et al. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis 2011, 17:141-151.
31. Sandborn W.J., Schreiber S., Hanauer S.B., et al. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PreCiSE 4 study. Clin Gastroenterol Hepatol 2010, 8:696-702.
32. Wagner C.L., Schantz A., Barnathan E., et al. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol 2003, 112:37-53.